--- title: "The Speed of Trust in the Age of AI: A Product Leader’s Perspective" description: Trust is the very foundation of our product development process at Acclinate. That principle must hold strong in an age when AI is accelerating. image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/The-Speed-of-Trust-in-the-Age-of-AI--A-Product-Leader%E2%80%99s-Perspective.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Health Equity](https://blog.acclinate.com/topic/health-equity) # The Speed of Trust in the Age of AI: A Product Leader’s Perspective Trust is the very foundation of our product development process at Acclinate. That principle must hold strong in an age when AI is accelerating. ![The Speed of Trust in the Age of AI: A Product Leader’s Perspective ](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/The-Speed-of-Trust-in-the-Age-of-AI--A-Product-Leader%E2%80%99s-Perspective.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Rosemary Sherrod](https://app.hubspot.com/settings/avatar/4cf55da95c9ab7f24e539827f0f3fff9) [Rosemary Sherrod](https://blog.acclinate.com/author/rosemary-sherrod) Product Lead, Acclinate Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/the-speed-of-trust-in-the-age-of-ai-a-product-leaders-perspective) [**](https://twitter.com/home?status=https://blog.acclinate.com/the-speed-of-trust-in-the-age-of-ai-a-product-leaders-perspective) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/the-speed-of-trust-in-the-age-of-ai-a-product-leaders-perspective&title=The%20Speed%20of%20Trust%20in%20the%20Age%20of%20AI:%20A%20Product%20Leader’s%20Perspective) Stay up to date Get news directly in your inbox When I joined Acclinate, one phrase from our co-founder, Tiffany Whitlow, immediately took root in both my product mind and my heart: “We can only move at the speed of trust.” That wisdom hit me differently.  As the product lead responsible for shaping digital experiences that serve underrepresented communities, I carry those words with me daily. We're not only building a tech product. We’re building a space where real people, from real communities, can feel seen, heard, and safe—whether they engage with wellness content, tell their health stories, or take the courageous step to learn more about clinical research.  Trust is the very foundation of our product development process at Acclinate. And that principle must hold strong in an age when AI is accelerating faster than ever before.  ## When AI Enters the Chat in Healthcare As a product leader in healthcare technology, I’m constantly balancing the evolving needs of our community with the push to innovate. AI has exploded into every conversation. It’s fast. It’s flashy. And it’s everywhere—[85% of healthcare leaders are investing or plan on investing in AI](https://www.healthcarefinancenews.com/news/healthcare-leaders-target-ai-and-automation-address-financial-operational-pressures).  But it also brings hard questions to the surface:  - How do we integrate AI in ways that honor the trust we’ve worked so hard to earn? - Where can AI serve as a complement to—not a replacement for—the human connection that defines health and healing?  AI holds immense potential. But if we’re not intentional, it can also erode the very relationships we aim to deepen. And when you’re working with communities that have been historically excluded or mistreated by health systems, the cost of getting it wrong is too high.  ## **Building Trust-Centered Innovation**  So, how do we move forward as product teams striving for both innovation and inclusion? At Acclinate, and specifically through our NOWINCLUDED community, we’ve developed an [intentional framework for integrating AI](https://blog.acclinate.com/beyond-the-buzz-building-ai-that-solves-real-problems-in-healthcare) in a way that strengthens—not undermines—trust.  Here’s how we’re doing it:  ### **1. AI That Amplifies, Not Replaces**  We don’t use AI to speak *for* our community. Rather, we use it to *lift* their voices.  In practice, that means developing tools that highlight patterns in the stories people share, or surface trends in community conversations. AI can help us identify common health concerns, recurring questions, or emerging needs more efficiently. All while our members remain empowered to tell their stories.  At its heart, our approach acknowledges that empathy should never be automated. But that doesn’t mean visibility can’t be scaled with human-centered technology. We’re exploring how AI can make it easier for underrepresented voices to be seen, valued, and better understood. Not flattened. Not filtered.  ### **2. Inclusive Healthcare AI, By Design**  Inclusion doesn’t happen by accident. Especially not with AI.  We’ve committed to interrogating every AI tool or model we explore. And we start by asking harder questions during the research phase:  - Who trained this model? - What data was it trained on? - Who is excluded in that dataset?  Then we pressure-test new tools through the lens of bias, transparency, and representation. If they don’t align with the people we serve, they don't make it into our product. Inclusive design means more than accessibility. It means building with intentional equity—proactively closing the gaps that traditional technology often widens.  ### **3. Community-Centered Feedback Loops**  We don’t release AI-driven features without asking our community first, and we don’t stop asking after launch. Every AI touchpoint we consider goes through a feedback loop grounded in three questions:  - Is it **helpful**? - Is it **respectful**? - Does it **enhance understanding**, or create a new barrier?  We invite NOWINCLUDED members into our product process early. If a new feature doesn’t build trust, it doesn’t go live. Full stop. Trust isn’t just earned once. It has to be renewed with every interaction, update, and decision. **[Learn more about how Acclinate incorporates AI into its community-first approach.](https://blog.acclinate.com/e-dict-transforms-clinical-trial-recruitment).** ### **4. AI for Smarter Development, Not Just Faster Delivery**  Yes, AI helps us work faster. But we don’t believe in speed for speed’s sake.  We use AI to support product development—by helping us prototype quicker, identify trends, or generate early ideas. But we still pause. We still test. We still validate. Most importantly, we still listen first.  AI is a tool, and trust is the compass. And if one ever starts pulling us away from the other, we course-correct. Progress doesn’t mean sacrificing intention. In healthcare, where decisions affect people’s bodies and lives, we have a responsibility to move with care.  ### **5. The Future Is Slow… on Purpose**  In the race toward innovation, it’s easy to get swept up in acceleration. Faster deployment. Instant insights. Personalized everything.  But when you build for communities that have been ignored, harmed, or erased by health systems, slowness is a virtue. Taking your time means:  - Asking more questions. - Listening to more stories. - Reviewing feedback before iterating. - Choosing accuracy over convenience.  As product leaders, we need to resist the pressure to deliver tech just because it’s trending. Our job isn’t just to build fast—it’s to build *right*.  ## **What Trust Looks Like in Practice**  At Acclinate, trust shows up in how we approach every decision:  - It shows up in how we prioritize transparency when explaining AI-driven recommendations. - It shows up in how we protect user data and ensure consent is clear and ongoing. - It shows up in how we design for connection, not just conversion.  This approach isn’t always the fastest route to a flashy product launch. But it is the most enduring.  And in healthcare—especially among Black and Brown communities—durability matters. Because trust broken once is exponentially harder to rebuild. ## **A Word to Fellow Product Leaders in Health Tech**  If you’re also navigating how to integrate AI into your healthcare product, here’s my advice:  **Use AI to deepen relationships, not just data points.**  **Use it to inform decisions, not replace the people they impact.**  **Use it to reflect the values of your community—not just the ambitions of your roadmap.**  Innovation without intention is just noise. Innovation that listens first is how we build something that lasts. It’s how we develop AI-powered products that don’t just work, but *resonate*. And it's how we move at the speed of trust.  Ready to learn more about Acclinate’s ground-up approach to tech development? [Schedule a 1:1 with our team](https://blog.acclinate.com/cs/c/?cta_guid=55107ccc-ffdc-40cd-9072-0f0f1408baae&signature=AAH58kEm_uCx10Tx20Q44DDlOpe3GvufhA&utm_referrer=https%3A%2F%2Fwww.acclinate.com%2F&portal_id=19943632&pageId=153327030564&placement_guid=2e1c34dc-aaa1-43b8-b5f4-469b0db4e302&click=d96517a7-9f9c-4fc4-bc9b-be45e540e3dc&redirect_url=APefjpHURiZCDLyK0CnmEgkqisTBnIlLNuYxCh8XEGGiOcmODF-W2axAuiPR--slCMyisKWetbrNWGSfmB6oftFzsiyEmnaJwfaY4vykOQLBZBFSyR83TbpIf1nzwfXU9pEbOy5e7nyfSm2zGr6Pt0ZwwbMTvYmJgx7Ck4X203cCezqKvGK3TvZ6Fj20PQ4V_-nN-P34BEpgEmTn6H4JUHfhpvBXRp-9rXLapbEdSdUxevdJ4Pstr7o&hsutk=af2d6b60f434b25264f6c24b1b4bd070&canon=https%3A%2F%2Fblog.acclinate.com%2F&ts=1752453147892).  ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Rosemary Sherrod", "url" : "https://blog.acclinate.com/author/rosemary-sherrod" }, "dateModified" : "2025-07-22T13:00:04.467Z", "datePublished" : "2025-07-22T13:00:00.000Z", "headline" : "The Speed of Trust in the Age of AI: A Product Leader’s Perspective", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/The-Speed-of-Trust-in-the-Age-of-AI--A-Product-Leader%E2%80%99s-Perspective.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/the-speed-of-trust-in-the-age-of-ai-a-product-leaders-perspective", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```